Free Trial

Capricor Therapeutics (CAPR) News Today

Capricor Therapeutics logo
$13.28 +0.13 (+0.99%)
As of 04/24/2025 04:00 PM Eastern
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Trading 4.8% Higher - Here's Why
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 4.8% - Here's Why
Capricor Therapeutics Inc stock logo
Capricor Therapeutics Inc (NASDAQ:CAPR) Stock Holdings Increased by Geode Capital Management LLC
Geode Capital Management LLC raised its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 37.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 879,468 shares of the biotechnology company's stock after
Capricor Therapeutics Inc stock logo
EAM Investors LLC Has $528,000 Position in Capricor Therapeutics Inc (NASDAQ:CAPR)
EAM Investors LLC decreased its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 45.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,276 shares of the biotechnol
Capricor Therapeutics Inc stock logo
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by Altium Capital Management LLC
Altium Capital Management LLC lifted its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 150.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 714,000 shares of the biotechnology company's stock
Capricor Therapeutics Inc stock logo
144,250 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Acquired by Kennedy Capital Management LLC
Kennedy Capital Management LLC purchased a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 144,250 shares of the biotechnology company's
Capricor Therapeutics Inc stock logo
Wellington Management Group LLP Invests $565,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)
Wellington Management Group LLP purchased a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 40,959 shares of the biotec
Capricor Therapeutics Inc stock logo
Vanguard Group Inc. Purchases 700,243 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)
Vanguard Group Inc. raised its position in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 44.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,276,784 shares of the biotechnology company's stock after acquiring an additional 7
Capricor Therapeutics Inc stock logo
Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Rating of "Buy" by Brokerages
Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have earned a consensus rating of "Buy" from the six brokerages that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokera
Capricor Therapeutics Inc stock logo
Cantor Fitzgerald Issues Positive Outlook for CAPR Earnings
Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Research analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for Capricor Therapeutics in a report issued on Tuesday, April 1st. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will earn ($1.
Capricor Therapeutics Inc stock logo
Swiss National Bank Acquires New Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)
Swiss National Bank acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 67,400 shares of the biotechnology company's stock, valued at approximate
Capricor Therapeutics Inc stock logo
Charles Schwab Investment Management Inc. Has $1.54 Million Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)
Charles Schwab Investment Management Inc. raised its stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 51.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 111,336 shares of the biotechnology company's
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.7% - Here's What Happened
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 4.7% - Should You Sell?
Check Out What Whales Are Doing With CAPR
Capricor Therapeutics Inc stock logo
Bank of New York Mellon Corp Purchases 20,638 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)
Bank of New York Mellon Corp boosted its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 32.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 84,027 shares of the biotechnology c
Capricor Therapeutics Inc stock logo
What is HC Wainwright's Forecast for CAPR Q1 Earnings?
Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for Capricor Therapeutics in a report issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn ($0.35) per share for the quart
Capricor Therapeutics Inc stock logo
Research Analysts Offer Predictions for CAPR Q2 Earnings
Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Capricor Therapeutics in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst J. Pantginis expects
Capricor Therapeutics Inc stock logo
Capricor Therapeutics Target of Unusually High Options Trading (NASDAQ:CAPR)
Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of unusually large options trading activity on Thursday. Investors acquired 11,316 call options on the stock. This represents an increase of approximately 214% compared to the typical volume of 3,599 call options.
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up After Strong Earnings
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up After Better-Than-Expected Earnings
Capricor Therapeutics Inc stock logo
Cantor Fitzgerald Reiterates Overweight Rating for Capricor Therapeutics (NASDAQ:CAPR)
Cantor Fitzgerald restated an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday.
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Announces Earnings Results, Beats Expectations By $0.15 EPS
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.
Q4 2024 Capricor Therapeutics Inc Earnings Call
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6% - What's Next?
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6% - What's Next?
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Receives Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday.
Capricor Therapeutics announces long-term data from HOPE-2 OLE study
Capricor Therapeutics Inc stock logo
Capricor Therapeutics Inc (NASDAQ:CAPR) Given Average Rating of "Buy" by Analysts
Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has been given a consensus rating of "Buy" by the six analysts that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have
Capricor Therapeutics receives FDA acceptance of BLA for deramiocel
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Trading 6.6% Higher - Should You Buy?
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.6% - Here's What Happened
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Trading 6.6% Higher - Still a Buy?
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.6% - Here's Why
Get Capricor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.

CAPR Media Mentions By Week

CAPR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CAPR
News Sentiment

0.74

0.73

Average
Medical
News Sentiment

CAPR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CAPR Articles
This Week

5

4

CAPR Articles
Average Week

Get Capricor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CAPR) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners